It was reported on August 11 that the CRO sector rose.
Among individual stocks, Tiger Pharmaceuticals performed well, with an increase of more than 8%.
Zhaoyan New Drug and Medicilon rose by more than 5%.
In addition, Yaoshi Technology, Asymchem, etc.
Follow up
.
In recent years, the CRO sector can be said to be a very popular pharmaceutical segment
.
On the one hand, Asymchem announced on August 4 that it will use its own funds within 12 months from the announcement date to repurchase up to 2.
7586 million shares of the company through centralized bidding transactions, involving funds of not less than 400 million yuan and not more than 800 million yuan
.
Affected by this news, the stock price went higher.
As of the close on the 4th, Asymchem's stock price rose 9.
24% to close at 173.
8 yuan per share
.
In addition, the entire CXO sector has strengthened as a whole, and the stock prices of many companies, including Zhaoyan New Drug and Tigermed, both rose and rose on the day
.
On the other hand, recently, Kanglong Chemical announced that the actual controller of the company and its persons acting in concert are expected to reduce their holdings by no more than 27.
75 million shares, accounting for 2.
33% of the company's total share capital.
Calculated based on the stock price on the day of the announcement, its reduced shares correspond to the market value of the shares.
About 2.
2 billion yuan
.
According to public information, Kanglong Chemical has been frequently reduced by important shareholders since 2022, including the company's first, fifth and sixth largest shareholders
.
It can be seen that pharmaceutical companies have reduced their holdings and increased their holdings.
So, is CRO still worth looking forward to?
From the perspective of performance, as of now, among the pharmaceutical companies that have disclosed their semi-annual reports, the ones with outstanding performance include Asymchem, Proton, etc.
, and their performance growth has exceeded 100%
.
Among them, Proton shares is expected to achieve a net profit of 1.
191 billion yuan to 1.
212 billion yuan in the first half of the year, a year-on-year increase of 455%-465%
.
Asymchem's semi-annual performance forecast released on the evening of July 14 shows that it is expected to achieve a net profit of 1.
644 billion yuan to 1.
743 billion yuan, a year-on-year increase of 282.
99% to 305.
97%
.
In addition, the performance of Haite Bio, Zhaoyan New Drug, WuXi AppTec, and Kyushu Pharmaceuticals are also expected to achieve growth, with an increase of more than 20% in the first half of the year
.
It can be seen that the overall performance of the interim report of the leading companies in the CXO sector is relatively good, and there is a certainty of continued rapid growth in the future with sufficient orders in hand
.
The industry believes that the CXO sector is still a high-growth track in the pharmaceutical industry.
The performance forecast generally exceeds market expectations.
The follow-up will enter the intensive disclosure period with the interim report, which is expected to boost market confidence
.
From the perspective of CRO's medium and long-term market, the prospects are still optimistic in the industry
.
In recent years, China's innovative drug industry has developed rapidly, but drug R&D has the characteristics of high cost, long cycle, and high R&D difficulty.
The existence of pharmaceutical outsourcing companies can be said to help pharmaceutical companies improve R&D efficiency and reduce their operating costs
.
In this regard, the industry believes that CRO is in line with the general trend of the future development of the pharmaceutical industry.
With the rapid development of China's emerging pharmaceutical market and more and more multinational pharmaceutical companies entering China's pharmaceutical market, the CRO industry will usher in new opportunities.
Enterprises have more development opportunities
.
Southwest Securities once mentioned in the research report that, driven by cost advantages, overseas CXO production capacity continues to shift to China, and the rise of domestic innovative drugs further brings incremental space for the CXO industry.
Sex is higher
.
Huaan Securities pointed out that compared with developed countries, the development of China's CRO industry is still in its infancy, and there is huge room for development.
In the next few years, China's CRO market will maintain a compound annual growth rate of 29.
4%, reaching 17.
2 billion in 2023.
USD, of which the clinical research stage CRO market will reach USD 13.
3 billion
.
